Skip to content
Home » Amgen (AMGN) CEO Bob Bradway on Q2 2014 Results – Earnings Call Transcript

Amgen (AMGN) CEO Bob Bradway on Q2 2014 Results – Earnings Call Transcript

Source: Seeking Alpha

 

Amgen (NASDAQ:AMGN)

Q2 2014 Results Earnings Conference Call

July 29, 2014, 5:00 p.m. ET

Executives

Arvind Sood – VP of Investor Relations

Bob Bradway – Chairman and CEO

David Meline – CFO

Tony Hooper – Head of Global Commercial Operations

Sean Harper – Head of R&D

Analysts

Matthew Harrison – Morgan Stanley

Robyn Karnauskas – Deutsche Bank

Eric Schmidt – Cowen & Company

Terence Flynn – Goldman Sachs

Geoffrey Porges – Sanford C. Bernstein

Josh Schimmer – Piper Jaffray

Yaron Werber – Citi

Mark Schoenebaum – ISI Group

Michael Yee – RBC Capital Markets

Geoff Meacham – JPMorgan

Matt Roden – UBS

Eun Yang – Jefferies

Ian Somaiya – Nomura Securities

Ravi Mehrotra – Credit Suisse

Howard Liang – Leerink Swann

Operator

My name is Marvin, and I will be your conference facilitator today for Amgen’s second quarter earnings conference call. [Operator instructions.] I would now like to introduce Arvind Sood, vice president of investor relations. Mr. Sood, you may now begin.

Arvind Sood – VP of Investor Relations

Okay, thank you, Marvin. Good afternoon, everybody. I’d like to welcome you to our conference call to review our operating results for the second quarter. Our new CFO, and my new boss, David Meline, actually picked a great quarter to join us, as our business performance was strong across the board.

Our CEO, Bob Bradway will introduce David formally in just a couple of minutes, and will also review our strategic progress and actions we are taking to position ourselves for long term growth. Following Bob, David will review our second quarter performance.

Our head of global commercial operations, Tony Hooper, will then discuss our product performance during the quarter and trends that we see going forward. Following Tony, our head of R&D, Sean Harper will provide a brief update on the many late-stage opportunities we have in our pipeline, as well as progress we are making on regulatory submissions. After Sean’s comments, Bob will make a few concluding comments, and then we should have plenty of time for Q&A.

Pages: First |1 | ... | Next → | Last | View Full Transcript